Author:
al Alabdullah Muslim Abdulrazzaq A.,Goodarzi Mohammad Taghi,Homayouni Tabrizi Masoud
Abstract
AbstractEntrapping phytochemical bioactive compounds into nano-structured biocompatible polymers has been successfully utilized for improving cancer treatment efficiency. Silibinin is a potent compound that shows promising anticancer properties. In the present study, the Zein-β-cyclodextrin complex was used to encapsulate silibinin and evaluate the induced cell death type and cytotoxic impacts on human cancer cells. The silibinin-loaded Zein-β cyclodextrin nano-carriers (SZBC-NCs) were synthesized utilizing a gradual ultrasound-mediated homogenization technique and characterized by Zeta potential, DLS, FESEM, and FTIR analysis. The SZBC-NCs’ antioxidant activity was studied by conducting ABTS and DPPH radical scavenging assays. Finally, the SZBC-NCs selective toxicity and cellular death induction mechanism were studied on the HT-29 and AGS cancer cells by measuring the cell survival and apoptotic gene (Caspase 3, 9), respectively, which were verified by conducting the DAPI staining analysis. The negatively charged (− 27.47 mV) nanoparticles (286.55 nm) showed significant ABTS and DPPH radical scavenging activity. Moreover, the remarkable decrease in the IC50 concentrations of the SZBC-NCs among the HT-29 and AGS cancer cell lines exhibited their selective cytotoxic potential. Also, the overexpressed apoptotic (Caspases 3 and 9) and down-regulated necrotic (NFKB) gene expressions following the SZBC-NCs treatment doses indicated the apoptotic activity of SZBC-NCs, which were verified by the increased apoptotic morphology of the DAPI-stained HT-29 cancer cells. The antioxidant and colon cancer cell-related apoptotic activity of the SZBC-NCs make it an appropriate anti-colon cancer nano delivery system. Therefore, they can potentially be used as a safe efficient colon cancer treatment strategy. However, further in vivo experiments including animal cancer models have to be studied.
Publisher
Springer Science and Business Media LLC
Reference36 articles.
1. Morgan, E. et al. The current and future incidence and mortality of gastric cancer in 185 countries, 2020–40: A population-based modelling study. EClinicalMedicine 47, 101404 (2022).
2. Sharma, R. et al. Global, regional, and national burden of colorectal cancer and its risk factors, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol. Hepatol. 7(7), 627–647 (2022).
3. Peters, J. M. & Gonzalez, F. J. The evolution of carcinogenesis. Toxicol. Sci. 165(2), 272–276 (2018).
4. Hashemy, S. I. & Seyedi, S. M. R. ROS impacts on cell cycle checkpoint signaling in carcinogenesis. In Handbook of Oxidative Stress in Cancer: Mechanistic Aspects (eds Hashemy, S. I. & Seyedi, S. M. R.) 1–19 (Springer, 2021).
5. Devarajan, E. et al. Down-regulation of caspase 3 in breast cancer: A possible mechanism for chemoresistance. Oncogene 21(57), 8843–8851 (2002).